MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- PANACEA BIOTECH - MYLAN (US)
PANACEA BIOTECH vs MYLAN (US) - Comparison Results
PANACEA BIOTECH Change
Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 PANACEA BIOTECH  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| PANACEA BIOTECH Mar-19 |
MYLAN Dec-18 |
PANACEA BIOTECH/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 354 | 3,561 | - | |
| Low | Rs | 138 | 1,960 | - | |
| Sales per share (Unadj.) | Rs | 74.6 | 1,638.8 | - | |
| Earnings per share (Unadj.) | Rs | 6.7 | 44.5 | - | |
| Cash flow per share (Unadj.) | Rs | 15.5 | 351.3 | - | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 57.2 | 1,772.8 | - | |
| Shares outstanding (eoy) | m | 61.25 | 514.50 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 3.3 | 1.7 | 195.8% | |
| Avg P/E ratio | x | 36.8 | 62.0 | 59.3% | |
| P/CF ratio (eoy) | x | 15.9 | 7.9 | 201.9% | |
| Price / Book Value ratio | x | 4.3 | 1.6 | 276.0% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 15,061 | 1,420,461 | 1.1% | |
| No. of employees | `000 | 2.3 | 35.0 | 6.6% | |
| Total wages/salary | Rs m | 1,471 | 0 | - | |
| Avg. sales/employee | Rs Th | 1,973.6 | 24,089.9 | 8.2% | |
| Avg. wages/employee | Rs Th | 635.6 | 0 | - | |
| Avg. net profit/employee | Rs Th | 176.8 | 654.1 | 27.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 4,567 | 843,147 | 0.5% | |
| Other income | Rs m | 45 | 0 | - | |
| Total revenues | Rs m | 4,612 | 843,147 | 0.5% | |
| Gross profit | Rs m | 2,030 | 218,175 | 0.9% | |
| Depreciation | Rs m | 540 | 157,870 | 0.3% | |
| Interest | Rs m | 1,048 | 40,552 | 2.6% | |
| Profit before tax | Rs m | 486 | 19,752 | 2.5% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 77 | -3,142 | -2.5% | |
| Profit after tax | Rs m | 409 | 22,895 | 1.8% | |
| Gross profit margin | % | 44.4 | 25.9 | 171.8% | |
| Effective tax rate | % | 15.9 | -15.9 | -99.7% | |
| Net profit margin | % | 9.0 | 2.7 | 329.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 2,415 | 470,812 | 0.5% | |
| Current liabilities | Rs m | 9,077 | 343,274 | 2.6% | |
| Net working cap to sales | % | -145.9 | 15.1 | -964.5% | |
| Current ratio | x | 0.3 | 1.4 | 19.4% | |
| Inventory Days | Days | 65 | 84 | 77.9% | |
| Debtors Days | Days | 71 | 93 | 76.0% | |
| Net fixed assets | Rs m | 8,333 | 163,557 | 5.1% | |
| Share capital | Rs m | 61 | 449 | 13.7% | |
| Net worth | Rs m | 3,504 | 912,131 | 0.4% | |
| Long term debt | Rs m | 461 | 984,482 | 0.0% | |
| Total assets | Rs m | 13,755 | 2,446,689 | 0.6% | |
| Interest coverage | x | 1.5 | 1.5 | 98.4% | |
| Debt to equity ratio | x | 0.1 | 1.1 | 12.2% | |
| Sales to assets ratio | x | 0.3 | 0.3 | 96.3% | |
| Return on assets | % | 10.6 | 2.6 | 408.6% | |
| Return on equity | % | 11.7 | 2.5 | 465.1% | |
| Return on capital | % | 38.7 | 3.2 | 1,217.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,049 | 175,206 | 0.6% | |
| From Investments | Rs m | -54 | -90,562 | 0.1% | |
| From Financial Activity | Rs m | -1,011 | -81,621 | 1.2% | |
| Net Cashflow | Rs m | -20 | 1,452 | -1.4% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 74.82 Rs / USD
Compare PANACEA BIOTECH With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare PANACEA BIOTECH With: ABBOTT INDIA FDC CADILA HEALTHCARE IPCA LABS ORCHID PHARMA
Today's Market
Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
Related Views On News
Most Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)
Apr 6, 2021Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
A Unique Sector for Short-Term Profits (Fast Profits Daily)
Apr 12, 2021This ignored sector could deliver big short-term profits.
More
